Momenta Phamaceuticals (MNTA) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Operating income (loss): -18.18M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Financial Fact:
Operating income (loss): -18.18M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $10.41 million. Momenta Phamaceuticals, Inc. reaffirmed FY2013 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Gouverneur Bancorp, Inc. (GOVB) Tops Q4 EPS by 23c
- Bayfirst Financial Corp (BAFN) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
